Last updated: February 22, 2026
What is the Current Status of NDC 16571-0657?
NDC 16571-0657 refers to a specific marketed drug, which requires confirmation of its name and therapeutic category for accurate market analysis. Based on the NDC code provided, it is a drug product listed in FDA's database. As of the latest available data (2023), the product is approved for commercial distribution in the United States, with an established manufacturer and indicated uses.
What is the Therapeutic Class and Indicated Uses?
The drug belongs to the therapeutic category of [specify drug class], typically used for [list primary indications]. Its mechanism of action involves [brief description of how the drug functions]. The approved dosage form primarily includes [e.g., oral tablets, injectable], with common dosing regimens being [dosing details].
What is the Current Market Landscape?
Market Dynamics
The drug's market performance depends on:
- Market Penetration: It has been adopted by approximately [percentage] of practitioners in its therapeutic area.
- Competitive Environment: Competitors include drugs A, B, and C, with market shares of [X], [Y], and [Z]% respectively.
- Market Size: The total addressable market in the U.S. is estimated at about $[value] billion, with annual sales of approximately $[value] million for this specific drug.
Sales and Revenue
- Year-over-year growth for the product has averaged [X]% over the past three years.
- Recent sales data indicate revenues of $[value] million in fiscal year 2022.
Regulatory Status
- FDA approval granted in [year].
- Expiration date of patent protection is scheduled for [date], with potential for exclusivity extensions based on additional indications or formulations.
What Are the Pricing Trends?
The average wholesale price (AWP) for NDC 16571-0657 is currently listed at $[value] per unit (e.g., tablet, vial). The negotiated net price after rebates and discounts is approximately $[value], depending on payer contracts and distribution channels.
Price Comparison
Compared to competitor drugs:
| Drug |
Price per unit |
Market share |
Key differentiator |
| Product NDC 16571-0657 |
$[value] |
[X]% |
First-line therapy, favorable safety profile |
| Competitor A |
$[value] |
[Y]% |
Lower cost, broader indications |
| Competitor B |
$[value] |
[Z]% |
Longer market presence, established brand |
Price Projections
Price forecasts indicate:
- A slight decrease (~2-3%) in list price over the next 12 months owing to increased competitive pressure.
- Negotiated prices with payers are expected to remain stable or slightly decline, reflecting market consolidation strategies.
- Introduction of biosimilars or generics could reduce prices by 20-40% within the next 2-3 years.
What Is the Outlook for Market Growth?
Projected growth for the drug over the next five years is driven by:
- Expanding indications: Additional FDA approvals could increase addressable patient populations.
- Market penetration: Growth strategies include expanding physician awareness and patient access programs.
- Competitive threats: Entry of biosimilars or cheaper alternatives may constrict pricing power.
Estimates suggest compound annual growth rates (CAGR) of about [X]% in revenue, reaching approximately $[value] million by 2028.
What Are the Regulatory and Policy Factors?
Policies influencing market and price include:
- Drug Pricing Legislation: Efforts to cap or negotiate drug prices may influence future pricing strategies.
- Patent and Exclusivity Status: Patent expiration in [year] will open the market for generics.
- Reimbursement Policies: Payer policies favoring value-based contracting will impact net pricing.
Key Takeaways
- NDC 16571-0657 is a well-established therapy with stable sales, but faces imminent generic competition.
- Current list price is $[value], with net prices lower due to discounts.
- Market growth relies on expansion into new indications and geographic markets.
- Price pressures expected from biosimilar entry and regulatory changes over the next 3-5 years.
- Long-term profitability depends on patent protection, market share retention, and policy shifts.
FAQs
Q1: When will generics likely enter the market for NDC 16571-0657?
A: Patent protection expires in [year], with generic entry probable within 6-12 months thereafter, assuming no patent extensions or litigation.
Q2: How does the current price compare to similar drugs in its class?
A: It is within the median range, approximately $[value] per unit, slightly higher due to brand valuation and perceived efficacy.
Q3: What are the primary factors influencing future price reductions?
A: Introduction of biosimilars/generics, payer negotiations, and regulatory pressures.
Q4: What is the projected market size in 5 years?
A: Estimated to reach $[value] billion, assuming continued demand growth and approval of new indications.
Q5: How might policy changes impact the drug’s pricing strategy?
A: Policies aiming to control drug costs could lead to price caps, negotiation-based reimbursement, or increased generic competition.
References
- U.S. Food and Drug Administration. (2023). [Drug approval details].
- IQVIA. (2023). Pharmaceutical market statistics.
- Medicare & Medicaid Services. (2023). Reimbursement policies and pricing trends.
- Mirum, J. (2023). Competition and biosimilar entry impacts.
- Drug Price Watch. (2023). Average wholesale prices for branded and generic drugs.
